Acute Kidney Injury in Elderly Patients With Chronic Kidney Disease: Do Angiotensin-Converting Enzyme Inhibitors Carry a Risk?

Journal of Clinical Hypertension

Volumn 18, Issue 6, 2016, Pages 514-521

  Chaumont, Martin ^a   Pourcelet, Aline ^a   van Nuffelen, Marc ^a   Racapé, Judith ^b   Leeman, Marc ^a   Hougardy, Jean Michel ^a  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; HYDROCHLOROTHIAZIDE; INDAPAMIDE; SPIRONOLACTONE;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEHYDRATION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG OVERDOSE; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; EMERGENCY WARD; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; INCIDENCE; KIDNEY FUNCTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; CHEMICALLY INDUCED; COMPLICATION; HYPERTENSION; METABOLISM; REGRESSION ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; VERY ELDERLY;

ACUTE KIDNEY INJURY; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CROSS-SECTIONAL STUDIES; DRUG OVERDOSE; FEMALE; HUMANS; HYPERTENSION; MALE; REGRESSION ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES;

EID: 84963593286     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12795     Document Type: Article

References (34)

1. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825–830.
2. Onuigbo MAC, Onuigbo NTC. Late-onset renal failure from RAAS blockade. Kidney Int. 2006;70:1378–1379.
3. Ftouh S, Thomas M. Acute kidney injury: summary of NICE guidance. BMJ. 2013;347:f4930.
4. Eknoyan G, Lameire N, Eckardt KU, Kasiske BL. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138.
5. Canaud G, Bonventre JV. Cell cycle arrest and the evolution of chronic kidney disease from acute kidney injury. Nephrol Dial Transplant. 2015;30:575–583.
6. Suzuki H, Kanno Y, Ikeda N, et al. Selection of the dose of angiotensin converting enzyme inhibitor for patients with diabetic nephropathy depends on the presence or absence of left ventricular hypertrophy. Hypertens Res. 2002;25:865–873.
7. Smith TW, Morgan JP. Differences between angiotensin-converting enzyme inhibitors and receptor blockers. In: Bakris JP, ed. UpToDate. http://www.uptodate.com/contents/differences-between-angiotensin-converting-enzyme-inhibitors-and-receptor-blockers. Accessed December 29, 2015.
8. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
9. Kaukonen KM, Bailey M, Pilcher D, et al. Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med. 2015;372:1629–1638.
10. McGee S, Abernethy WB III, Simel DL. Is this patient hypovolemic? JAMA. 1999;281:1022–1029.
11. Wonnacott A, Meran S, Amphlett B, et al. Epidemiology and outcomes in community-acquired versus hospital-acquired AKI. Clin J Am Soc Nephrol. 2014;9:1007–1014.
12. Talabani B, Zouwail S, Pyart RD, et al. Epidemiology and outcome of community-acquired acute kidney injury. Nephrology. 2014;19:282–287.
13. Abdel-Kader K, Palevsky PM. Acute kidney injury in the elderly. Clin Geriatr Med. 2009;25:331–358.
14. GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857–1863.
15. Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med. 2006;354:131–140.
16. Brody H, Light DW. The inverse benefit law: how drug marketing undermines patient safety and public health. Am J Public Health. 2011;101:399–404.
17. Suzuki H, Kikuta T, Inoue T, Hamada U. Time to re-evaluate effects of renin-angiotensin system inhibitors on renal and cardiovascular outcomes in diabetic nephropathy. World J Nephrol. 2015;4:118.
18. O'Hare AM, Hailpern SM, Pavkov ME, et al. Prognostic implications of the urinary albumin to creatinine ratio in veterans of different ages with diabetes. Arch Intern Med. 2010;170:930–936.
19. Sarafidis PA, Bakris GL. Does evidence support renin-angiotensin system blockade for slowing nephropathy progression in elderly persons? Ann Intern Med. 2009;150:731–733.
20. O'Hare AM, Choi AI, Bertenthal D, et al. Age affects outcomes in chronic kidney disease. J Am Soc Nephrol. 2007;18:2758–2765.
21. Onuigbo MA, Onuigbo NT. Late-onset renal failure from angiotensin blockade (LORFFAB) in 100 CKD patients. Int Urol Nephrol. 2008;40:233–239.
22. Ahmed AK, Kamath NS, El Kossi M, El Nahas AM. The impact of stopping inhibitors of the renin–angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant. 2010;25:1344–1345.
23. Kent DM, Jafar TH, Hayward RA, et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol. 2007;18:1959–1965.
24. Stirling C, Houston J, Robertson S, et al. Diarrhoea, vomiting and ACE inhibitors–an important cause of acute renal failure. J Hum Hypertens. 2003;17:419–423.
25. National Confidential Enquiry Into Patient Outcome and Death Smith N, Stewart J, FindlayG. Acute kidney injury: adding insult to injury. http://www.ncepod.org.uk/2009aki.htm. Accessed January 27, 2016.
26. Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005;16:3365–3370.
27. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor–associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160:685–693.
28. Coca SG, Garg AX, Swaminathan M, et al; TRIBE-AKI Consortium. Preoperative angiotensin-converting enzyme inhibitors and angiotensin receptor blocker use and acute kidney injury in patients undergoing cardiac surgery. Nephrol Dial Transplant. 2013;28:2787–2799.
29. Auron M, Harte B, Kumar A, Michota F. Renin-angiotensin system antagonists in the perioperative setting: clinical consequences and recommendations for practice. Postgrad Med J. 2011;87:472–481.
30. Barodka V, Silvestry S, Zhao N, et al. Preoperative renin-angiotensin system inhibitors protect renal function in aging patients undergoing cardiac surgery. J Surg Res. 2011;167:e63–e69.
31. Shah M, Jain AK, Brunelli SM, et al. Association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use prior to major elective surgery and the risk of acute dialysis. BMC Nephrol. 2014;15:53.
32. Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379:165–180.
33. Wu HC, Wang WJ, Chen YW, Chen HH. The association between the duration of postoperative acute kidney injury and in-hospital mortality in critically ill patients after non-cardiac surgery: an observational cohort study. Ren Fail. 2015;37:985–993.
34. Coca SG, King JT, Rosenthal RA, et al. The duration of postoperative acute kidney injury is an additional parameter predicting long-term survival in diabetic veterans. Kidney Int. 2010;78:926–933.